# Delineate the Role of GSTP1 in Advanced Prostate Cancer

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $467,334

## Abstract

PROJECT SUMMARY/ABSTRACT
Prostate cancer is the second leading cause of cancer associated deaths in men in the United States. The first
line of treatment for men with advanced metastatic prostate cancer is hormone therapy. Although initial
responses are observed, unfortunately, the disease commonly recurs in its aggressive hormone therapy-
resistant form, which is largely responsible for prostate cancer-specific mortality. Thus, there is an urgent need
to define the mechanisms that drive the aggressive disease and develop novel strategies to overcome advanced
treatment-resistant prostate cancer.
We have recently shown that GSTP1 protein is significantly upregulated in treatment-resistant prostate cancer.
We have strong preliminary evidence suggesting that GSTP1 may play functional role in driving aggressive
prostate cancer and may represent a promising therapeutic target for the advanced disease. We have recently
demonstrated that GSTP1 is significantly elevated in hormone therapy-resistant prostate cancer and that
inhibition of GSTP1 suppresses prostate cancer growth.
The main goals of the proposed project are:
1) test the functional role of GSTP1 in advanced prostate cancer.
2) test the therapeutic potential of GSTP1 inhibition alone and in combination with cisplatin in aggressive
 prostate cancer in pre-clinical settings utilizing patient-derived xenograft (PDX) models of NEPC.
3) Delineate the mechanism of action of GSTP1 in advanced prostate cancer.
Successful completion of the proposed research will lead to: 1) defining the role of GSTP1 in aggressive therapy-
resistant prostate cancer and 2) direct new strategies regarding novel therapeutic interventions to combat the
deadly form of the disease.

## Key facts

- **NIH application ID:** 10607918
- **Project number:** 1R01CA274978-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Tanya I Stoyanova
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $467,334
- **Award type:** 1
- **Project period:** 2023-07-14 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10607918

## Citation

> US National Institutes of Health, RePORTER application 10607918, Delineate the Role of GSTP1 in Advanced Prostate Cancer (1R01CA274978-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10607918. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*